People: Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

2 Oct 2015
Change (% chg)

$8.25 (+5.23%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Hallal, David 

Mr. David L. Hallal is Chief Executive Officer, Director of Alexion Pharmaceuticals, Inc., since April 1, 2015. Mr. Hallal will no longer serve as Chief Operating Officer. He has been with Alexion since June 2006 and has served as Executive Vice President and Chief Commercial Officer since October 2012. Since joining Alexion, Mr. Hallal has served in senior commercial positions, including Senior Vice President, US Commercial Operations from June 2006 until November 2008, Senior Vice President, Commercial Operations Americas from November 2008 to May 2010, and then Senior Vice President, Global Commercial Operations from May 2010 until October 2012. Prior to joining Alexion, Mr. Hallal served as Vice President, Sales at OSI Eyetech from April 2004 until June 2006, where he led the U.S. launch of a first-in-class anti-VEGF therapy for age-related macular degeneration. Prior to OSI Eyetech, from 1992 until 2004, Mr. Hallal held various sales and marketing leadership positions at Amgen and Biogen Idec, where he was involved in multiple product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal received a B.A. in Psychology from the University of New Hampshire.

Basic Compensation

Total Annual Compensation, USD 696,058
Restricted Stock Awards, USD 3,268,430
Long-Term Incentive Plans, USD --
All Other, USD 3,550,120
Fiscal Year Total, USD 7,514,610

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 30,000 5,088,460.00
Name Fiscal Year Total

Leonard Bell


David Hallal


Vikas Sinha


Clare Carmichael


John Moriarty


Martin Mackay

As Of  30 Dec 2014
Search Stocks